Indivior agrees to sell rights to psychotropic drug in China for up to $112.5m

Writer, Stock Market Wire
Monday, February 4, 2019 - 07:13

Indivior said Monday it had entered into an agreement to sell its rights to a psychotropic drug in China to Pukang for a total of up to $122.5m.

Terms of the transaction included a signing payment of $1.5m, $3.5m upon designation of the Sai Bo Song tablet as a Class II psychotropic drug by Chinese regulators, and $12.5m upon closing of the transaction, for a total of $17.5m in near-term payments.

Indivior would also receive an additional $105.0m based on certain technical assistance it provided to Pukang and the achievement of certain sales milestones during a ten-year period following the first commercial sale of the product in China, for a total of up to $122.5m.

The foregoing regulatory hurdles was expected to occur throughout 2019 and the transaction was targeted to close by end of fourth quarter of 2019, the company said.

'The divestiture of the Sai Bo Song tablet in China is consistent with Indivior's efforts to prioritize efforts on the long-term growth opportunities with our new depot assets, SUBLOCADE and PERSERIS,' said Shaun Thaxter, Chief Executive Officer of Indivior.

'This transaction helps us focus our resources on the highest return opportunities in the regions we know best, while ensuring patients in China have access to an important and transformational treatment.'


Related content

FTSE opens up 0.1% as investors eye crucial Brexit, US-China trade talks

UK stocks opened modestly higher on Tuesday as investors braced for the outcome of crucial Brexit and US-China trade negotiations taking place separately this week....

Tue, 15/10/2019 - 08:53


Indivior upgrades profit outlook on stronger-than-expected performance of opioid addiction drug

Drug company Indivior upgraded its full-year profit outlook following stronger-than-expected net revenue performance as sales of its opioid addiction treatment had fared better than expected...

Tue, 15/10/2019 - 08:02


Indivior profits rises in Q2 as opioid addiction treatment fares better than expected

Drugmaker Indivior reported a rise in profits on stronger-than-expected second-quarter performance, during which its opioid-addiction treatment loss less market share than expected following the launch...

Wed, 31/07/2019 - 09:53


Reckitt and Indivior soar on US settlement and shares in housebuilders lifted by property market data

“UK and Asian stocks followed the upwards trend seen last night in the US after the Fed signalled an interest rate cut. The FTSE 100...

Thu, 11/07/2019 - 11:20


Indivior raises guidance as opioid addiction treatment fares better than expected in H1

Drugmaker Indivior raised its earnings guidance on a stronger-than-expected first half, during which its opioid-addiction treatment loss less market share than expected following the launch...

Thu, 11/07/2019 - 08:26